Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.
Latest SPAC News: GreenLight Biosciences returns to private market, Jet.AI partners with Vegas Golden Knights and Cirrus Aviation, and True Velocity announces partnership with FN America
GreenLight returns to private market in $46M deal after taste of Wall Street
GreenLight Biosciences will seek its dream off Wall Street in a go-private deal less than two years after taking the special purpose acquisition company route there.
The company is returning to private life in a $45.5 million all-cash deal from a coalition led by Fall Line Capital, according to a Tuesday relaease. The agreement comes two months after GreenLight first disclosed that Fall Line was interested in scooping up the faltering RNA biotech. The deal was unanimously agreed upon by GreenLight’s board of directors.
JET.AI Partners With Vegas Golden Knights And Cirrus Aviation To Provide Fans With By-The-Seat Private Jet Experience To Away Games
Jet Token Inc. d/b/a Jet.AI, an innovative private aviation, artificial intelligence, booking and membership platform and Cirrus Aviation, a leading private jet provider, have announced an official partnership with the Vegas Golden Knights to provide fans the ultimate private aviation experience for away games.
This partnership comes on the heels of Jet.AI’s recent announcement of a proposed business combination with Oxbridge Acquisition Corp. (NASDAQ: OXAC).
True Velocity Partners with FN America to Develop M240 Conversion Kit
Texas-based advanced technology company TV Ammo, Inc. announced today a strategic development partnership with FN America that would enable one of the most prolific machine guns in the world to fire its proprietary 6.8TVCM composite-cased cartridge.
As previously announced on November 1, 2022, TV Ammo, Inc. entered into a business combination agreement with Breeze Holdings Acquisition Corp. (NASDAQ: BREZ).READ
AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer
AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision oncology therapeutics, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating AUM001 for the treatment of metastatic colorectal cancer (MSS CRC). AUM001 is a mRNA translation inhibitor that targets MNK 1/2 and the chokepoint of multiple pro-oncogenic signalling pathways for the treatment of MSS CRC.
As previously announced on October 20, 2022, AUM entered into a definitive business combination agreement with Mountain Crest Acquisition Corp. V (Nasdaq: MCAG).READ
Latest SPAC Liquidations: Schultze Special Purpose Acquisition Corp. II Schultze Special Purpose Acquisition Corp. II (SAMA) to Liquidate on October 11, 2023 Schultze Special Purpose Acquisition Corp. II (Nasdaq: SAMA), announced that it will redeem all of the outstanding shares of its Class A common stock effective as of October 11, 2023. The Company expects...
Mercato Partners Acquisition Corporation (NASDAQ:MPRA) announced this afternoon via 8-K that its shareholders have approved its combination with Nuvini at a special meeting held earlier today. With 79.74% of the voting power of the Common Stock participating in the vote, the combination was overwhelmingly approved. 7,975,698 shares were recorded voting for the transaction, while only 38,008...
Home Plate Acquisition Corporation (NASDAQ:HPLT) announced that it adjourned this morning’s extension vote without conducting any business and it will pick things up again at 11 am ET October 2. Shareholders at the meeting are to consider giving Home Plate an extra two and half months to complete a deal, moving its deadline from October...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Law firm Schulte sues SPAC over fees from failed Philippine casino merger U.S. law firm Schulte Roth & Zabel is suing its former client 26 Capital Acquisition Corp to recover more than $1.9 million in legal fees...
Fortune Rise Acquisition Corp. (NASDAQ:FRLA) announced this morning that it has changed the target of its letter of intent to combine, but only partially. The SPAC had an existing LOI to merge with its own sponsor, but since that sponsor is now a subsidiary of another company it has to combine with a different version...